<DOC>
	<DOCNO>NCT00322946</DOCNO>
	<brief_summary>Dengue fever , cause dengue virus , major health problem tropical subtropical region world . The purpose study evaluate safety immune response dengue vaccine DEN4delta30-4995 healthy adult .</brief_summary>
	<brief_title>Safety Immune Response Dengue Virus Vaccine ( rDEN4delta30-4995 ) Healthy Adults</brief_title>
	<detailed_description>Dengue viruses account 50 million case dengue fever half million case severe disease , dengue hemorrhagic fever/dengue shock syndrome . Infection dengue virus lead cause hospitalization death child least eight Asian country . The goal produce vaccine dengue fever induce long-lived antibody response four dengue serotypes . The rDEN4delta30-4995 vaccine candidate live attenuate recombinant virus derive rDEN4delta30 protection dengue virus serotype 4 . The purpose study evaluate safety , reactogenicity , immunogenicity rDEN4delta30-4995 healthy adult . This study last 180 day ( 6 month ) . Participants Cohort 1 randomly assign receive high dose rDEN4delta30 placebo study entry . Participants Cohort 2 randomly assign receive low dose rDEN4delta30 placebo . Participants Cohort 3 randomly assign receive low dose rDEN4delta30 placebo . Cohorts 2 3 begin safety review participant previous cohort . After initial vaccination , participant Cohort 1 follow every day first 16 day study , monitoring temperature three time day Day 16 record measurement diary . After Day 16 , study visit occur Days 21 , 28 , 42 , 180 include physical exam blood collection . Some participant also ask undergo skin biopsy additional blood collection select visit .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult male nonpregnant female 18 50 year age Good general health Available duration study Willing use acceptable method contraception duration study Significant neurologic , cardiac , lung , liver , rheumatologic , autoimmune , kidney disease Behavioral , cognitive , psychiatric disease , opinion investigator , may interfere study Significant laboratory abnormality Medical , work , family problem result alcohol illegal drug use within 12 month prior study entry History severe allergic reaction anaphylaxis Severe asthma HIV1 serotype infect Hepatitis C virus ( HCV ) infect Hepatitis B surface antigen positive Immunodeficiency syndrome Use corticosteroid immunosuppressive medication within 2 week prior study entry . Individuals use topical nasal corticosteroid exclude . Live vaccine within 4 week prior study entry Killed vaccine within 2 week prior study entry Absence spleen Blood product within 6 month prior study entry Previous dengue virus flavivirus ( e.g. , yellow fever virus , St. Louis encephalitis , West Nile virus ) infection Prior receipt yellow fever dengue vaccine ( licensed experimental ) Plans travel area dengue infection common Received investigational agent within 30 day prior study entry Other condition , opinion investigator , would affect participation study Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Dengue Fever</keyword>
	<keyword>Dengue Vaccine</keyword>
	<keyword>Dengue Virus</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>Dengue Shock Syndrome</keyword>
</DOC>